Skip to main content
. 2026 Jan 19;5(2):102542. doi: 10.1016/j.jacadv.2025.102542

Table 4.

Clinical Outcomes Stratified by Lipoprotein(a) Group

Lp(a) >230 nmol/L
(n = 446)
Lp(a) ≤7 nmol/L
(n = 223)
P Value
Diagnosis of obstructive CAD 95 (21.3%) 28 (12.6%) 0.006
Revascularization (PCI or CABG) 92 (20.6%) 25 (11.2%) 0.003
Repeat revascularization (PCI or CABG) 36 (8.1%) 7 (3.1%) 0.014
First myocardial infarction 77 (17.3%) 22 (9.9%) 0.011
 STEMI 34 (7.6%) 8 (3.6%) 0.042
 NSTEMI 35 (7.8%) 12 (5.4%) 0.239
 Silent myocardial infarction 8 (1.8%) 2 (0.9%) 0.367
Recurrent myocardial infarction 26 (5.8%) 1 (0.4%) <0.001
 STEMI 11 (2.5%) 0 (0%) 0.018
 NSTEMI 15 (3.4%) 1 (0.4%) 0.020
Ischemic stroke 36 (8.1%) 10 (4.5%) 0.084
Peripheral arterial disease 31 (7.0%) 10 (4.5%) 0.210

Obstructive CAD was defined as the presence of ≥50% stenosis in at least one coronary vessel with a diameter of ≥1.5 mm on invasive coronary angiography, or a history of PCI or CABG. Data are presented as number of patients with percentages in brackets.

CABG = coronary artery bypass grafting; NSTEMI = non–ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; other abbreviations as in Tables 2 and 3.